The first major update in nearly two decades to U.S. regulations governing research misconduct by biomedical scientists has evoked a diverse range of reactions. The proposed changes aim to enhance transparency, efficiency, and equity in addressing allegations of research misdeeds among federally funded scientists. However, stakeholders express mixed sentiments about the potential impact of the revamped rules.
The proposed updates, issued by the federal Office of Research Integrity (ORI), introduce several modifications. Notably, universities would have a shorter timeframe to decide whether to pursue allegations against a faculty member, increased record-keeping requirements, and restrictions on swiftly closing cases deemed as "honest error." While the changes preserve the existing definition of misconduct, they also streamline the appeals process for those contesting a guilty finding.
Sheila Garrity, the director of ORI, emphasizes the goal of soliciting community feedback for a more effective review process. The proposed changes, outlined in a Notice of Proposed Rulemaking (NPRM), aim to provide greater clarity to the assessment of allegations and the subsequent investigative procedures.
University administrators hold diverse views on the proposed alterations. Some appreciate the clarification in gray areas but express concerns about the potential administrative burden, inefficiencies, and negative outcomes resulting from overly prescriptive measures. Julia Behnfeldt, a research integrity officer at Ohio State University, describes the changes as a "mixed bag," acknowledging positive aspects while highlighting potential drawbacks.
One contentious proposal involves splitting a university's initial response to an allegation into two stages—assessment and inquiry. The introduction of a 30-day time limit for the assessment phase, intended to expedite the process, is met with concerns about efficiency and fairness. The prohibition on citing "honest error" as a dismissal reason during the initial assessment or inquiry stage raises questions about consistency.
The proposal also suggests more formal record-keeping during the inquiry stage, including the use of a stenographer to record testimony and meticulous labeling of evidence. While intended to ensure proper conduct during inquiries, critics argue that such measures could deter individuals from coming forward with complaints.
Another noteworthy change involves the simplification of the appeals process for scientists contesting a finding of misconduct. This modification aims to use existing administrative records, reducing redundancy and improving efficiency in the appeals procedure.
However, one proposal facing skepticism is the expanded authority for ORI to publicize institutional findings of misconduct and disciplinary actions, even without government action. Concerns arise about potential damage to reputations, especially if released information allows for the identification of individuals involved, despite assurances from ORI regarding confidentiality.
As the comment deadline of January 4, 2024, approaches, the biomedical research community remains divided on the potential impact of these proposed changes. Stakeholders weigh the need for increased efficiency and transparency against concerns about potential unintended consequences and the safeguarding of individuals' reputations.
